{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T18:21:54Z","timestamp":1785090114359,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015425","name":"Department of Public Health Sciences, University of Rochester Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015425","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.modpat.2026.100988","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T17:20:35Z","timestamp":1772558435000},"page":"100988","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Investigating Genetic Risk to Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Colorectal Cancer Through Routinely Available Next-Generation Sequencing Data"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5783-4562","authenticated-orcid":false,"given":"Mengxue","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela D.","family":"Gaudio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Parente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Setia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.modpat.2026.100988_bib1","first-page":"285","article-title":"Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica","volume":"57","author":"Bras","year":"1954","journal-title":"AMA Arch Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.100988_bib2","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/annonc\/mdl386","article-title":"Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery","volume":"18","author":"Rubbia-Brandt","year":"2007","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2026.100988_bib3","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cld.2010.07.009","article-title":"Sinusoidal obstruction syndrome","volume":"14","author":"Rubbia-Brandt","year":"2010","journal-title":"Clin Liver Dis"},{"issue":"1","key":"10.1016\/j.modpat.2026.100988_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2017.87","article-title":"Pathologic assessment of gastrointestinal tract and pancreatic carcinoma after neoadjuvant therapy","volume":"31","author":"Pai","year":"2018","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.modpat.2026.100988_bib5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jhep.2013.04.014","article-title":"Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model","volume":"59","author":"Robinson","year":"2013","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.modpat.2026.100988_bib6","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","article-title":"Sinusoidal obstruction syndrome (hepatic veno-occlusive disease)","volume":"4","author":"Fan","year":"2014","journal-title":"J Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.modpat.2026.100988_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/jpm11050347","article-title":"Genetic predictors for sinusoidal obstruction syndrome-a systematic review","volume":"11","author":"Waespe","year":"2021","journal-title":"J Pers Med"},{"issue":"3","key":"10.1016\/j.modpat.2026.100988_bib8","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/bjc.2012.590","article-title":"Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer","volume":"108","author":"Vreuls","year":"2013","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.modpat.2026.100988_bib9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2174\/156800912800190901","article-title":"DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment","volume":"12","author":"Solier","year":"2012","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.modpat.2026.100988_bib10","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.1840040121","article-title":"Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors","volume":"4","author":"McDonald","year":"1984","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.modpat.2026.100988_bib11","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"issue":"26","key":"10.1016\/j.modpat.2026.100988_bib12","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1182\/blood-2014-03-551630","article-title":"How I treat sinusoidal obstruction syndrome","volume":"123","author":"Chao","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.modpat.2026.100988_bib13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/1751-2980.12177","article-title":"Histological features and severity of oxaliplatin-induced liver injury and clinical associations","volume":"15","author":"Nalbantoglu","year":"2014","journal-title":"J Dig Dis"},{"issue":"3","key":"10.1016\/j.modpat.2026.100988_bib14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","article-title":"Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer","volume":"15","author":"Rubbia-Brandt","year":"2004","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100988_bib15","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12885-016-2998-2","article-title":"Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis","volume":"17","author":"Stevenson","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.modpat.2026.100988_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jmoldx.2016.07.012","article-title":"Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established amplicon sequencing assays","volume":"19","author":"Kadri","year":"2017","journal-title":"J Mol Diagn"},{"issue":"22","key":"10.1016\/j.modpat.2026.100988_bib18","doi-asserted-by":"crossref","first-page":"4023","DOI":"10.1093\/bioinformatics\/btab440","article-title":"Detecting copy number alterations in RNA-Seq using SuperFreq","volume":"37","author":"Flensburg","year":"2021","journal-title":"Bioinformatics"},{"issue":"5","key":"10.1016\/j.modpat.2026.100988_bib19","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jmoldx.2023.02.004","article-title":"Detection of biallelic loss of dna repair genes in formalin-fixed, paraffin-embedded tumor samples using a novel tumor-only sequencing panel","volume":"25","author":"Glodzik","year":"2023","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.modpat.2026.100988_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.20892\/j.issn.2095-3941.2016.0004","article-title":"Current practices and guidelines for clinical next-generation sequencing oncology testing","volume":"13","author":"Strom","year":"2016","journal-title":"Cancer Biol Med"},{"issue":"6","key":"10.1016\/j.modpat.2026.100988_bib21","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1158\/1078-0432.CCR-10-2169","article-title":"ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis","volume":"17","author":"Yin","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"53","key":"10.1016\/j.modpat.2026.100988_bib22","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.18632\/oncotarget.27140","article-title":"Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin","volume":"10","author":"Rao","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.modpat.2026.100988_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820924194","article-title":"Chemotherapy-associated liver injury in colorectal cancer","volume":"13","author":"Gangi","year":"2020","journal-title":"Therap Adv Gastroenterol"},{"issue":"15","key":"10.1016\/j.modpat.2026.100988_bib24","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1200\/JCO.2009.25.2106","article-title":"Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05","volume":"28","author":"Boige","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2026.100988_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/tpj.2012.31","article-title":"A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil\/leucovorin\/oxaliplatin (FOLFOX4) regimen","volume":"13","author":"Cecchin","year":"2013","journal-title":"Pharmacogenomics J"},{"issue":"3","key":"10.1016\/j.modpat.2026.100988_bib26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/bcp.12631","article-title":"DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan","volume":"80","author":"Falvella","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.modpat.2026.100988_bib27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.alit.2024.03.003","article-title":"Clinical characteristics and genetic HLA marker for patients with oxaliplatin-induced adverse drug reactions","volume":"73","author":"Hsu","year":"2024","journal-title":"Allergol Int"},{"issue":"10","key":"10.1016\/j.modpat.2026.100988_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078053","article-title":"Evaluating predictive pharmacogenetic signatures of adverse events in colorectal cancer patients treated with fluoropyrimidines","volume":"8","author":"Jennings","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.modpat.2026.100988_bib29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/annonc\/mdw074","article-title":"Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)","volume":"27","author":"Kanai","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2026.100988_bib30","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/bjc.2011.17","article-title":"Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity","volume":"104","author":"Kim","year":"2011","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.modpat.2026.100988_bib31","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/bjc.2013.479","article-title":"S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis","volume":"109","author":"Kim","year":"2013","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.modpat.2026.100988_bib32","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/147323001003800313","article-title":"Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients","volume":"38","author":"Kristensen","year":"2010","journal-title":"J Int Med Res"},{"issue":"4","key":"10.1016\/j.modpat.2026.100988_bib33","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00280-013-2075-3","article-title":"Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer","volume":"71","author":"Lee","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"20","key":"10.1016\/j.modpat.2026.100988_bib34","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2009.21.7943","article-title":"Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741","volume":"28","author":"McLeod","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.modpat.2026.100988_bib35","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/tpj.2016.81","article-title":"Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies","volume":"17","author":"Meulendijks","year":"2017","journal-title":"Pharmacogenomics J"},{"issue":"10","key":"10.1016\/j.modpat.2026.100988_bib36","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1200\/JCO.2006.08.1844","article-title":"Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy","volume":"25","author":"Ruzzo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.modpat.2026.100988_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1352939","article-title":"NeuroPredict: study of the predictive value of ABCB1 genetic polymorphisms and associated clinical factors in chronic chemotherapy-induced peripheral neuropathy (CIPN)","volume":"15","author":"Vargas-Aliaga","year":"2024","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100988_bib38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0959-8049(02)00411-2","article-title":"Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines","volume":"39","author":"Arnould","year":"2003","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.modpat.2026.100988_bib39","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200622","article-title":"ERCC1 mutations impede DNA damage repair and cause liver and kidney dysfunction in patients","volume":"218","author":"Apelt","year":"2021","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.modpat.2026.100988_bib40","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1042\/CS20190124","article-title":"Local endothelial DNA repair deficiency causes aging-resembling endothelial-specific dysfunction","volume":"134","author":"Bautista-Ni\u00f1o","year":"2020","journal-title":"Clin Sci (Lond)"},{"issue":"2","key":"10.1016\/j.modpat.2026.100988_bib41","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/hep.24713","article-title":"A mouse model of accelerated liver aging caused by a defect in DNA repair","volume":"55","author":"Gregg","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.modpat.2026.100988_bib42","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3892\/mmr.2022.12862","article-title":"Model establishment and microarray analysis of mice with oxaliplatin-induced hepatic sinusoidal obstruction syndrome","volume":"26","author":"Zhu","year":"2022","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.modpat.2026.100988_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0022-2836(85)90276-1","article-title":"Synthetic oligonucleotide probes deduced from amino acid sequence data. theoretical and practical considerations","volume":"183","author":"Lathe","year":"1985","journal-title":"J Mol Biol"},{"issue":"1-2","key":"10.1016\/j.modpat.2026.100988_bib44","first-page":"13","article-title":"A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues","volume":"382","author":"Yu","year":"1997","journal-title":"Mutat Res"},{"issue":"6","key":"10.1016\/j.modpat.2026.100988_bib45","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.cell.2015.02.029","article-title":"Codon optimality is a major determinant of mRNA stability","volume":"160","author":"Presnyak","year":"2015","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.modpat.2026.100988_bib46","first-page":"555","article-title":"Comparison of two human ovarian carcinoma cell lines (A2780\/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene","volume":"16","author":"Yu","year":"2000","journal-title":"Int J Oncol"},{"issue":"4","key":"10.1016\/j.modpat.2026.100988_bib47","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/07357907.2014.998834","article-title":"The predictive role of ERCC1 status in oxaliplatin based neoadjuvant therapy for metastatic colorectal cancer (mCRC) to the liver","volume":"33","author":"Geva","year":"2015","journal-title":"Cancer Invest"},{"key":"10.1016\/j.modpat.2026.100988_bib48","series-title":"FoundationOne\u00ae CDx Technical Information (SPEC-01197 V4.0): Comprehensive Genomic Profiling of 324 Genes. Foundation Medicine Inc","author":"Inc","year":"2025"},{"issue":"1","key":"10.1016\/j.modpat.2026.100988_bib49","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.124.001049","article-title":"Innovation in cancer pharmacotherapy through integrative consideration of germline and tumor genomes","volume":"77","author":"Tremmel","year":"2025","journal-title":"Pharmacol Rev"},{"issue":"1","key":"10.1016\/j.modpat.2026.100988_bib50","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40364-020-00213-4","article-title":"Application of pharmacogenetics in oncology","volume":"8","author":"Miteva-Marcheva","year":"2020","journal-title":"Biomark Res"},{"key":"10.1016\/j.modpat.2026.100988_bib51","article-title":"Integration of germline pharmacogenetics into a tumor sequencing program","volume":"2","author":"Hertz","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.modpat.2026.100988_bib52","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41525-022-00283-3","article-title":"Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic exome sequencing data","volume":"7","author":"Lanillos","year":"2022","journal-title":"NPJ Genom Med"},{"issue":"3","key":"10.1016\/j.modpat.2026.100988_bib53","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jmoldx.2016.01.003","article-title":"Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade","volume":"18","author":"Ji","year":"2016","journal-title":"J Mol Diagn"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0893395226000311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:05:46Z","timestamp":1779282346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0893395226000311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0893395226000311"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2026.100988","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating Genetic Risk to Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Colorectal Cancer Through Routinely Available Next-Generation Sequencing Data","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2026.100988","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100988"}}